11th Oct 2021 12:58
Oxford Cannabinoid Technologies Holdings PLC - London-based pharmaceutical company developing prescription cannabinoid medicines - Signs new partnerships to target chronic pain condition trigeminal neuralgia. Partnerships include a new supply agreement with Georgia, US-based Purisys for cannabinoid active pharmaceutical ingredients to be used in preclinical drug development and future commercial supplies. Also partners with pharmaceutical services firm Oz-UK Ltd for the development of a cannabinoid metered dose inhaler formulation. Finally, announces extension of partnership with Voisin Consulting Life Sciences to help develop regulatory strategy around products.
Oxford Cannabinoid focusses on medicines that mimic the painkilling effects of cannabis. With current treatments only partially effective and with adverse side-effects, it is aiming to provide a drug-device combination product for trigeminal neuralgia sufferers.
"We are delighted to have further expanded our portfolio," comments Chief Executive John Lucas. "The pain caused by trigeminal neuralgia can be extremely debilitating and we are looking forward to working towards a pain management solution with our partners."
Current stock price: 2.82 pence
Year-to-date change: down 44% since May IPO
By Will Paige; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
OCTP.L